Curevac N.V. (CVAC) has released an update.
CureVac N.V., a leader in mRNA technology, has partnered with MD Anderson Cancer Center to co-develop mRNA-based cancer vaccines targeting high-need hematological and solid tumor indications. Leveraging CureVac’s expertise in mRNA vaccine design and manufacturing, alongside MD Anderson’s prowess in translational and clinical research, the collaboration is set to lead Phase 1/2 studies with the goal of crafting off-the-shelf therapeutic solutions for cancer patients. CureVac holds exclusive rights to any late-stage development and commercialization of the vaccine candidates emerging from this partnership.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.
